Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Jean Louis Selam"'
Autor:
Elisabetta Torlone, Reena Thomas, Philip Home, David Kerr, Geremia B. Bolli, Jean Louis Selam, Agnès Sola-Gazagnes, Ester Vitacolonna
Publikováno v:
Diabetes Care
OBJECTIVE Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) and multiple daily injections (MDIs) with insulin glargine as basal insulin and mealtime insulin lispro have not been prospectively compared in people naïve to either r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7d57b5ad64afaa9fdad5cdf4d93c9f
https://doi.org/10.2337/dc08-1874
https://doi.org/10.2337/dc08-1874
Autor:
Jean Louis Selam, Luigi F. Meneghini
Publikováno v:
Advances in Therapy. 26:194-207
The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy.PREDI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::168b26a488d13bab8456e8a4bcae8cc4
https://doi.org/10.1007/s12325-009-0007-8
https://doi.org/10.1007/s12325-009-0007-8
Publikováno v:
Current Medical Research and Opinion. 24:11-20
PREDICTIVE 303 was a 26-week, prospective, randomized, open-label, multi-center study in patients with type 2 diabetes that investigated whether patient-driven adjustments of insulin detemir doses using the 303 Algorithm achieved similar glycemic con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fd4d630fa3f07303e16c009c166624
https://doi.org/10.1185/030079908x242755
https://doi.org/10.1185/030079908x242755
Autor:
P. Urios, Jacques Peyroux, M. Sternberg, Jocelyne M'bemba, Jean-Louis Selam, Anne-Marie Borsos, Gérard Slama
Publikováno v:
Clinical biochemistry. 49(3)
Objective Advanced glycation end products (AGEs) of collagens appear to contribute to microvascular complications in diabetes. Do high concentrations of AGEs in skin collagen predict accelerated progression of these complications after 6 years and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fbc92fe2d4b42dbd28ff5764b4b5eba
https://pubmed.ncbi.nlm.nih.gov/26506116
https://pubmed.ncbi.nlm.nih.gov/26506116
Autor:
Jean Louis Selam
Publikováno v:
Diabetes Research and Clinical Practice. 74:S123-S126
The use of CSII is progressively growing throughout the world, however a number of factors interfere with its diffusion and produce wide disparity between different countries. In USA around 20–25% of the population of Type 1 diabetics is treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b658060f66fc6339444444b6fd066ebb
https://doi.org/10.1016/s0168-8227(06)70014-6
https://doi.org/10.1016/s0168-8227(06)70014-6
Autor:
Jean Louis Selam
Publikováno v:
Expert Opinion on Pharmacotherapy. 4:1373-1377
A non-invasive alternative to insulin injections would represent a major improvement for Type 1 and 2 insulin-treated patients. The lung is the only route which allows bio-availability of insulin, approaching 10% without absorption enhancers. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa10c38ba26c479e5c8d96579fd1b673
https://doi.org/10.1517/14656566.4.8.1373
https://doi.org/10.1517/14656566.4.8.1373
Publikováno v:
Diabetes Care. 20:59-63
OBJECTIVE To examine the long-term benefits and risks of treatment of IDDM with an implantable programmable insulin pump. RESEARCH DESIGN AND METHODS Seventy-six patients with IDDM were studied at nine clinical centers. After 3–4 months of intensiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e815b268f6985486d778eb47db7581b2
https://doi.org/10.2337/diacare.20.1.59
https://doi.org/10.2337/diacare.20.1.59
Autor:
Brigitte Mace, Marie-Lou Ramaniche, Jean-Louis Selam, F. Bruzzo, Gérard Slama, M. J. Haardt, Catherine Dorange, Jean-Pierre Bethoux
Publikováno v:
Diabetes Care. 17:847-851
OBJECTIVE To investigate if intraperitoneal (IP) insulin infusion via programmable implantable pumps is a potential alternative to subcutaneous (SC) insulin via multiple injections. RESEARCH DESIGN AND METHODS We compared the cost-benefits of the two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76035de8e3f1c5d3fea28869f1518fcc
https://doi.org/10.2337/diacare.17.8.847
https://doi.org/10.2337/diacare.17.8.847
Autor:
Rimon, Mohammad Towhidul Islam1 (AUTHOR), Hasan, Md Wasif1 (AUTHOR), Hassan, Mohammad Fuad1 (AUTHOR), Cesmeci, Sevki1 (AUTHOR) scesmeci@georgiasouthern.edu
Publikováno v:
Pharmaceutics. Jul2024, Vol. 16 Issue 7, p944. 52p.
Autor:
Jean-Louis Selam
The first manufactured insulin pump was introduced in the 1970s and the first insulin pens in 1985; since then, many improvements have been made to both devices. The advantages of pens over syringes have been confirmed in numerous studies and include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62fb47d66cbab27fbbb08c55da877af9
https://europepmc.org/articles/PMC2901025/
https://europepmc.org/articles/PMC2901025/
